Cellular interactions are of fundamental importance, orchestrating organismal development, tissue homeostasis and immunity. Recently, powerful methods that use single-cell genomic technologies to dissect physically interacting cells have been developed. However, these approaches are characterized by low cellular throughput, long processing times and high costs and are typically restricted to predefined cell types. Here we introduce Interact-omics, a cytometry-based framework to accurately map cellular landscapes and cellular interactions across all immune cell types at ultra-high resolution and scale. We demonstrate the utility of our approach to study kinetics, mode of action and personalized response prediction of immunotherapies, and organism-wide shifts in cellular composition and cellular interaction dynamics following infection in vivo. Our scalable framework can be applied a posteriori to existing cytometry datasets or incorporated into newly designed cytometry-based studies to map cellular interactions with a broad range of applications from fundamental biology to applied biomedicine. Interact-omics, a high-throughput cytometry-based framework, resolves the cellular interaction landscape.
Fostering the Implementation of Liquid Biopsy in Clinical Practice: European Liquid Biopsy Society (ELBS) 2024 Meeting Report by Klaus Pantel et al. Journal of Experimental & Clinical Cancer Research Catherine Alix-Panabières
Proud to be part of the team that published this new #liquidbiopsy study! This study is the largest pooled analysis with globally collected individual patient…
Researchers developed a microfluidic platform using surface-enhanced Raman spectroscopy (SERS) to detect single pancreatic cancer cells. The platform successfully differentiated between cancer stages, offering a promising tool for early cancer diagnosis through molecular analysis of individual...
The scale of the plots presenting your flow cytometry data are actually critically important in getting good results with high dimensional data analysis. The…
How do we decide which fluorophores to use for spectral flow cytometry? Last week I suggested treating spectral cytometers just like conventional cytometers with lots of detectors. For the purpose of fluorophore selection, this means picking one fluorophore to peak in detector. I'll show some exceptions to this rule, and also show how they aren't as exceptional as they might first appear. The guidelines I'm presenting here are most important as you increase the size and complexity of your panels
The Center for Bioactive Delivery's Pobezinsky and Pobezinskaya have analyzed and described what they call the "mosquito effect," shedding light on how certain pathogens can outwit the body's immune system.
💫 Super excited to share our latest review just published in Nature Portfolio.
Liquid biopsies🩸, indicating the sampling of body fluids rather than solid-tissue biopsies, have the potential to revolutionize cancer care through personalized, noninvasive disease detection and monitoring. Circulating tumour DNA (#ctDNA) 🧬 and circulating tumour cells (#CTCs) are promising blood-based biomarkers in bladder cancer. Results from several studies have shown the clinical potential of ctDNA and CTCs in #bladder #cancer for prognostication, treatment-response monitoring, and early detection of minimal residual disease (#MRD) and disease recurrence. Following successful clinical trial evaluation, assessment of ctDNA and CTCs holds the potential to transform the therapeutic pathway for patients with bladder cancer — potentially in combination with the analysis of urinary tumour DNA — through tailored treatment guidance and optimized disease surveillance.
👏👏👏 Sia Viborg Lindskrog, Trine Strandgaard, Iver Nordentoft, Matthew Galsky, Tom Powles, Mads Agerbæk, Jørgen Bjerggaard Jensen, Catherine Alix-Panabières & Lars Dyrskjøt
🤩 Good reading !
CHU de Montpellier, Recherche et innovation – CHU de Montpellier, Renan Targhetta, Samir JABER Liquid Biopsy LCCRH Lab - Laboratoire Cellules Circulantes Rares Humaines 🩸 Aarhus University European Liquid Biopsy Society (ELBS) PANCAID, GUIDE.MRD OncoDaily | 11 comments on LinkedIn
Le score de Matutes, décrit par le Dr Matutes du Royal Marsden Hospital à Londres en 1994, est un score diagnostique de la leucémie lymphoïde chronique (LLC), la forme la plus fréquente de leucémie chronique chez l'adulte. Il est basé sur l'étude de l’expression, par cytomérie en flux, de 5 marqueurs de surface des lymphocytes B: le CD5, le CD23, le FMC7, le CD79b et l'intensité de l'immunoglobuline de surface. Un point est ou non attribué en fonction de l’expression de chaque marqueur, et un score supérieur ou égal à 4 est très en faveur du diagnostic de LLC. Dans les combinaisons d’anticorps utilisées en cytométrie en flux pour le diagnostic des hémopathies lymphoïdes B, est systématiquement présent le CD20 qui permet d'isoler la population B, c’est également une cible thérapeutique. L’anticorps anti FMC7 reconnaissant un épitope de la protéine CD20, il y a compétition entre les anticorps et l’étude du FMC7 nécessite donc un tube spécifique, actuellement en 8 couleurs/8 antigènes.
Les cytomètres de routine hospitalière passant de 8-10 couleurs à 12-13 couleurs, Valérie Bardet et ses collaborateurs de du Service d'Hématologie-Immunologie-Transfusion des Hôpitaux Universitaires Paris Ile de France-Ouest (UVSQ/UPSaclay, Boulogne-Billancourt) se sont demandés s'ils pouvaient remplacer l’étude du FMC7 par celle de l’intensité du CD20, ceci afin de limiter le nombre d’anticorps utilisés et donc le coût et le temps des techniques. Leur étude parue dans le British Journal of Haematology a été réalisée sur une cohorte de 508 patients atteints d’hémopathie lymphoïde B chronique provenant des hôpitaux Ambroise Paré et Saint Louis. Elle a permis de montrer qu’une nouvelle modalité de calcul était possible avec des performances égales au score historiquement décrit.
Légende Figure : Comparaison des résultats du calcul du score avec le FMC7 (barre de gauche) ou le CD20 (barre de droite) dans différents types d'hémopathies B (CLL, chronic lymphocytic leukaemia; DLBCL, diffuse large B‐cell lymphoma; FL, follicular lymphoma; HCL, hairy cell leukaemia; MCL, Mantle cell lymphoma; MZL, marginal zone lymphoma; SDRPL, splenic diffuse red pulp small B‐cell lymphoma; WM, Waldenström macroglobulinaemia)
Speaker Biography: Jordi Petriz received his BSc degree in Biochemistry and Animal Biology from the University of Barcelona. He then pursued his PhD at Barcelona after acceptance at the Cryobiology and Cell Therapy Department, Cancer Research Institute (IRO)...
Webinar: Flow cytometry as you have never seen it before
Webinar Abstract: The Invitrogen™ Attune™ CytPix Flow Cytometer can simultaneously collect fluorescence data and high-resolution brightfield images of individual cells. This allows to better understand the morphology of each cell population identified for analysis. The images can be used to study cell-cell interactions, rare event identification, and rapid confirmation of disease...
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.
Your new post is loading...
